Ceryvyn Therapeutics (OPTE.Y) Stock Overview

OPTE.Y fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (0.1x) is below the US market (19.2x)

Revenue is forecast to grow 42.22% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Makes less than USD$1m in revenue (A$-20K)

Earnings are forecast to decline by an average of 79.7% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($13M)

OPTE.Y Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW501,009 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

501,009 investors already sharing narratives

View all narratives

Ceryvyn Therapeutics Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ceryvyn Therapeutics
Historical stock prices
Current Share Price	AU$0.023
52 Week High	AU$3.17
52 Week Low	AU$0.0017
Beta	1.53
1 Month Change	-53.72%
3 Month Change	17.95%
1 Year Change	n/a
3 Year Change	-99.24%
5 Year Change	-99.69%
Change since IPO	-99.42%

Recent updates

Seeking Alpha • Jan 30

Opthea: Small Australian Company Aiming To Upend The Wet AMD Market

Summary Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD, showing promising Phase 2b results. Wet AMD treatments like Lucentis and Eylea have limitations; sozinibercept aims to improve efficacy by targeting a broader VEGF family. Financially, Opthea has a market cap of $797mn and a cash runway of 4-5 quarters, but faces transparency and dilution risks. Despite compelling data, market entry challenges and low trading volume make me cautious; I await topline data before investing. Read the full article on Seeking Alpha

Seeking Alpha • Nov 07

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate

Summary Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 results due in 2025. The wet AMD market is lucrative, but the challenge lies in the patient's willingness to receive two intravitreal injections for potentially better outcomes. Phase 2b results were promising, but Phase 3 studies face uncertainties due to different standards of care and longer study durations, amongst other reasons. Opthea's financial pressure and competitive landscape make it a risky investment; I assign a "Hold" rating pending Phase 3 outcomes. Read the full article on Seeking Alpha

Seeking Alpha • Aug 30

Opthea GAAP EPS of -$0.26 misses by $0.03

Opthea press release (NASDAQ:OPT): FY GAAP EPS of -$0.26 misses by $0.03. As of June 30, 2022, Opthea had cash, cash equivalents and short-term investments of $44.6 million.

Seeking Alpha • Aug 15

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Opthea (NASDAQ:OPT) entered into a non-dilutive financing transaction for up to $170M from investment funds working with Launch Therapeutics to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration. Launch Tx is the recently formed development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth. Under agreement terms, the funds managed by Carlyle and Abingworth, in collaboration with Launch Tx, will commit $120M in three installments at fixed time points and retain an option to commit another $50M. Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time. "This strategic transaction is expected to fund us through Phase 3 topline data expected in mid-2024 and strengthens our strategic position to maximize the value of OPT-30," CEO Dr Megan Baldwin commented.

Shareholder Returns

	OPTE.Y	US Biotechs	US Market
7D	-32.2%	4.0%	-0.7%
1Y	n/a	42.5%	20.3%

Return vs Industry: Insufficient data to determine how OPTE.Y performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how OPTE.Y performed against the US Market.

Price Volatility

Is OPTE.Y's price volatile compared to industry and market?
OPTE.Y volatility
OPTE.Y Average Weekly Movement	123.3%
Biotechs Industry Average Movement	10.4%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.2%

Stable Share Price: OPTE.Y's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: OPTE.Y's weekly volatility has decreased from 203% to 123% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1984	n/a	Jeremy Levin	opthea.com

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries.

Ceryvyn Therapeutics Limited Fundamentals Summary

How do Ceryvyn Therapeutics's earnings and revenue compare to its market cap?
OPTE.Y fundamental statistics
Market cap	US$13.28m
Earnings (TTM)	US$205.86m
Revenue (TTM)	n/a

0.1x

P/E Ratio

-952.0x

P/S Ratio

Is OPTE.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OPTE.Y income statement (TTM)
Revenue	-AU$20.12k
Cost of Revenue	AU$0
Gross Profit	-AU$20.12k
Other Expenses	-AU$296.99m
Earnings	AU$296.97m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	0.22
Gross Margin	100.00%
Net Profit Margin	-1,476,212.82%
Debt/Equity Ratio	0%

How did OPTE.Y perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/07 03:59
End of Day Share Price	2026/07/07 00:00
Earnings	2025/12/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ceryvyn Therapeutics Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Elyse Shapiro	Canaccord Genuity
John Savin	Edison Investment Research
Chris Cooper	Goldman Sachs

Ceryvyn Therapeutics (OPTE.Y) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Ceryvyn Therapeutics Limited Competitors

Oncotelic Therapeutics

Galera Therapeutics

Fortress Biotech

Spero Therapeutics

Price History & Performance

Recent News & Updates

Opthea Limited(NasdaqGS:OPT) dropped from NASDAQ Composite Index

Opthea Limited, Annual General Meeting, Nov 11, 2025

Opthea Limited Announces Departure of Sujal Shah as Director, Effective September 15, 2025

Opthea Limited Provides Corporate Update Following the Termination of Its Coast (Combination of OPT-302 with Aflibercept Study) and Shore ( Study of OPT-302 in Combination with Ranibizumab) Phase 3 Clinical Trials

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Limited Announces the Publication of Sozinibercept Phase 2B Data in the Peer-Reviewed Journal Ophthalmic Surgery, Lasers and Imaging Retina

Recent updates

Opthea Limited(NasdaqGS:OPT) dropped from NASDAQ Composite Index

Opthea Limited, Annual General Meeting, Nov 11, 2025

Opthea Limited Announces Departure of Sujal Shah as Director, Effective September 15, 2025

Opthea Limited Provides Corporate Update Following the Termination of Its Coast (Combination of OPT-302 with Aflibercept Study) and Shore ( Study of OPT-302 in Combination with Ranibizumab) Phase 3 Clinical Trials

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Limited Announces the Publication of Sozinibercept Phase 2B Data in the Peer-Reviewed Journal Ophthalmic Surgery, Lasers and Imaging Retina

Opthea Limited Completes Drug Product Ppq Campaign

Opthea Wet AMD Data Featured at Macula Society Meeting

Opthea: Small Australian Company Aiming To Upend The Wet AMD Market

Opthea Limited Announces Publication of Phase 1b Trial of Sozinibercept Combination Therapy in Diabetic Macular Edema

Opthea Limited Announces Board Changes

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate

Opthea Limited, Annual General Meeting, Nov 15, 2024

Opthea Limited Appoint Executives

Opthea Limited Announces Executive Changes

Opthea Limited Announces Board Appointments

Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million.

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Opthea Limited Announces Board Changes

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Opthea GAAP EPS of -$0.26 misses by $0.03

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Shareholder Returns

Price Volatility

About the Company

Ceryvyn Therapeutics Limited Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources